Oregon Health & Science University
Latest From Oregon Health & Science University
In Vivo's editors pick October's most significant deals, including bold moves from Vir Biotechnology and the birth of a major generics player. (Free article.)
Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised more than $500m and signed multiple collaboration agreements, including deals with Alnylam and Visterra worth as much as $1bn each.
Complexa topped the list of recent venture capital financings with a $62m Series C round, followed by Evelo and Kezar with $50m Series B rounds and LogicBio with a $45m Series B.
Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.